Novel regeneron bispecific antibodies show encouraging anti-tumor activity in two advanced solid tumors

First-in-class phase 1 data presented at esmo for ubamatamab (regn4018; muc16xcd3) in recurrent ovarian cancer and regn5093 (metxmet) in met-altered advanced non-small cell lung cancer tarrytown, n.y. , sept. 10, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive early data for two novel and investigational bispecific antibodies – ubamatamab (regn4018; muc16xcd3) in recurrent ovarian cancer and regn5093 (metxmet) in met-altered advanced non-small cell lung cancer (nsclc).
REGN Ratings Summary
REGN Quant Ranking